FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038402562> ?p ?o ?g. }

• W2038402562 endingPage "805" @default.
• W2038402562 startingPage "800" @default.
• W2038402562 abstract "Abstract Immune anaemias (IA) [auto‐immune haemolytic anaemia (AIHA) and pure red cell aplasia (PRCA)] are complications of chronic lymphocytic leukaemia (CLL). Fludarabine has been associated with AIHA, whereas both rituximab and cyclophosphamide have been used to treat this condition. Combining these agents with fludarabine may reduce the likelihood of AIHA. We report on the incidence, outcome and pretreatment predictors of IA in 300 patients treated with fludarabine, cyclophosphamide and rituximab (FCR). Nineteen patients (6·5%) developed IA [AIHA (5·8%), PRCA (0·7%)] on or after treatment with FCR. Most patients (82·4%) with AIHA had a negative direct antiglobulin test (DAT). Additional markers of haemolysis (indirect hyperbilirubinaemia, reticulocytosis, low haptoglobin and elevated lactate dehydrogenase levels) confirmed the presence of AIHA in these patients. The majority of patients responded to therapies including steroids, ciclosporin, i.v. immunoglobulin, etc. High pretreatment levels of beta‐2 microglobulin predicted for development of IA. No haemolytic crisis was observed during FCR therapy in eight patients with AIHA prior to FCR. Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates. The diagnosis of AIHA can be considered even if the DAT is negative. Pre‐existing AIHA need not preclude front‐line FCR therapy." @default.
• W2038402562 created "2016-06-24" @default.
• W2038402562 creator A5006104041 @default.
• W2038402562 creator A5015140142 @default.
• W2038402562 creator A5027575595 @default.
• W2038402562 creator A5035354255 @default.
• W2038402562 creator A5038307470 @default.
• W2038402562 creator A5055045706 @default.
• W2038402562 creator A5061285204 @default.
• W2038402562 creator A5084379902 @default.
• W2038402562 creator A5089428686 @default.
• W2038402562 date "2007-03-01" @default.
• W2038402562 modified "2023-10-17" @default.
• W2038402562 title "Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors" @default.
• W2038402562 cites W1499296962 @default.
• W2038402562 cites W1756818535 @default.
• W2038402562 cites W1903703315 @default.
• W2038402562 cites W1964100413 @default.
• W2038402562 cites W1973950224 @default.
• W2038402562 cites W1979475418 @default.
• W2038402562 cites W1981933562 @default.
• W2038402562 cites W1982068700 @default.
• W2038402562 cites W1986651388 @default.
• W2038402562 cites W1987153929 @default.
• W2038402562 cites W2005090731 @default.
• W2038402562 cites W2008472399 @default.
• W2038402562 cites W2010701770 @default.
• W2038402562 cites W2038252730 @default.
• W2038402562 cites W2038396294 @default.
• W2038402562 cites W2046221853 @default.
• W2038402562 cites W2059172186 @default.
• W2038402562 cites W2062395913 @default.
• W2038402562 cites W2066015434 @default.
• W2038402562 cites W2072800027 @default.
• W2038402562 cites W2073929083 @default.
• W2038402562 cites W2082253535 @default.
• W2038402562 cites W2087225207 @default.
• W2038402562 cites W2125134816 @default.
• W2038402562 cites W2133054066 @default.
• W2038402562 cites W2148637565 @default.
• W2038402562 cites W2161926682 @default.
• W2038402562 cites W2165505664 @default.
• W2038402562 cites W2165507228 @default.
• W2038402562 cites W2167813535 @default.
• W2038402562 cites W2572600111 @default.
• W2038402562 cites W4293241248 @default.
• W2038402562 cites W60865865 @default.
• W2038402562 cites W96780237 @default.
• W2038402562 doi "https://doi.org/10.1111/j.1365-2141.2007.06513.x" @default.
• W2038402562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17341265" @default.
• W2038402562 hasPublicationYear "2007" @default.
• W2038402562 type Work @default.
• W2038402562 sameAs 2038402562 @default.
• W2038402562 citedByCount "84" @default.
• W2038402562 countsByYear W20384025622012 @default.
• W2038402562 countsByYear W20384025622013 @default.
• W2038402562 countsByYear W20384025622014 @default.
• W2038402562 countsByYear W20384025622015 @default.
• W2038402562 countsByYear W20384025622016 @default.
• W2038402562 countsByYear W20384025622017 @default.
• W2038402562 countsByYear W20384025622018 @default.
• W2038402562 countsByYear W20384025622019 @default.
• W2038402562 countsByYear W20384025622020 @default.
• W2038402562 countsByYear W20384025622021 @default.
• W2038402562 countsByYear W20384025622022 @default.
• W2038402562 countsByYear W20384025622023 @default.
• W2038402562 crossrefType "journal-article" @default.
• W2038402562 hasAuthorship W2038402562A5006104041 @default.
• W2038402562 hasAuthorship W2038402562A5015140142 @default.
• W2038402562 hasAuthorship W2038402562A5027575595 @default.
• W2038402562 hasAuthorship W2038402562A5035354255 @default.
• W2038402562 hasAuthorship W2038402562A5038307470 @default.
• W2038402562 hasAuthorship W2038402562A5055045706 @default.
• W2038402562 hasAuthorship W2038402562A5061285204 @default.
• W2038402562 hasAuthorship W2038402562A5084379902 @default.
• W2038402562 hasAuthorship W2038402562A5089428686 @default.
• W2038402562 hasBestOaLocation W20384025621 @default.
• W2038402562 hasConcept C126322002 @default.
• W2038402562 hasConcept C159654299 @default.
• W2038402562 hasConcept C203014093 @default.
• W2038402562 hasConcept C2776694085 @default.
• W2038402562 hasConcept C2776755627 @default.
• W2038402562 hasConcept C2777422296 @default.
• W2038402562 hasConcept C2777799521 @default.
• W2038402562 hasConcept C2777938653 @default.
• W2038402562 hasConcept C2778248108 @default.
• W2038402562 hasConcept C2778461978 @default.
• W2038402562 hasConcept C2778986270 @default.
• W2038402562 hasConcept C2779263901 @default.
• W2038402562 hasConcept C2779338263 @default.
• W2038402562 hasConcept C2780653079 @default.
• W2038402562 hasConcept C71924100 @default.
• W2038402562 hasConcept C90924648 @default.
• W2038402562 hasConceptScore W2038402562C126322002 @default.
• W2038402562 hasConceptScore W2038402562C159654299 @default.
• W2038402562 hasConceptScore W2038402562C203014093 @default.
• W2038402562 hasConceptScore W2038402562C2776694085 @default.
• W2038402562 hasConceptScore W2038402562C2776755627 @default.

• next